Shots:

• The P-III (KINECT-HD) study evaluates the efficacy, safety & tolerability of valbenazine (qd) vs PBO in 128 adults aged 18 to 75yrs. with chorea associated with HD
• The study met the 1EPs i.e., reduction in chorea movements as measured by a change in the UHDRS TMC score from baseline to the avg. score @10 & 12wks. & a mean reduction in TMC score of 3.2 units while 2EPs of CGI-C Response Status & PGI-C Response were also in favor of valbenazine treatment. The results will be presented at a medical conference in 2022
• The treatment-emergent AEs were consistent with the known safety profile of valbenazine, no suicidal behavior was observed. The company is planning to submit sNDA to the US FDA in 2022

 Ref: PR Newswire | Image: Neurocrine